Tuesday, June 15, 2010

Stock Watch Power 3 medical (PWRM.OB)

Power 3 Medical Products Inc., Traded as PWRM.OB
This is the 2nd in a series of articles showcasing Power3 Medical’s dedication and perseverance in the field of proteomics and the identification of disease.

Power3 Medical’s Discovery Platform

Through years of expertise, Power3 has developed a structured approach to the discovery and development of protein footprints and biomarkers of human disease. The company’s Discovery Platform is a 7-step process that creates intellectual property through clinically focused, precise, and controlled analysis.

The Discovery Platform

How the process works:

Patient Samples
A major component of the discovery process is obtaining clinically relevant patient samples. Power3 Medical receives patient samples for two defined purposes.
> Research samples are provided to Power3 under approved research agreements and protocols. The samples are provided by physician scientists seeking answers to pressing unmet clinical needs. The purpose of these studies is to discover biomarkers and protein footprints of human disease for intellectual property development, publication, and presentation at scientific meetings.
> Clinical Trial Study samples are received for the purposes of single site and multiple sites clinical studies under approved clinical trial protocols for Phase I, II, or III, for commercialization purposes.

Sample PreparationWhen patient samples arrive at the Power3 laboratory, they are in a sub optimal biological form. The samples must be properly prepared for optimal analysis by utilizing appropriate procedures for their sample type. The critical specific methods employed here are proprietary to the company.
3. 2-Dimensional Gel Electrophoresis (2DE)
The Power3 Medical scientific team specializes in 2-D gel analysis, and utilizes 2DE to transform the highly complex mixture of proteins into its constituents and to ferret out the clinically important disease footprints. This approach, the gold standard of proteomics, was pioneered by Dr. Goldknopf in the 1970’s-80’s. In the first dimension, proteins are resolved according to their electric charge. The second dimension separates the proteins according to their size. Due to very high sensitivity of detection and measurement, reproducibility, and resolution, in the hands of Power3, the 2D gel technology allows the visualization and measurement of 2-20 times as many proteins in clinical samples simultaneously.

    No comments: